Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children-Reference-Cited by-同舟云学术

Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children

Published:2024-09 Issue: Volume: Page:
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Pecenka Clint,Sparrow Erin,Feikin Daniel R,Srikantiah Padmini,Darko Delese Mimi,Karikari-Boateng Eric,Baral Ranju,Vizzotti Carla,Rearte Analia,Jalang'o Rose,Fleming Jessica A,Martinón-Torres Federico,Karron Ruth A

Funder

Bill & Melinda Gates Foundation

Publisher

Elsevier BV

Reference56 articles.

1. For a pivotal vaccine: trial, error, and two young lives;Schulson,2023

2. The journey to RSV vaccines—heralding an era of structure-based design;Graham;N Engl J Med,2023

3. Structural characterization of a human Fc fragment engineered for extended serum half-life;Oganesyan;Mol Immunol,2009

4. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis;Li;Lancet,2022

5. Sanofi gets drug regulator nod to market RSV therapy in India;Pilla,2024

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early-life respiratory syncytial virus disease and long-term respiratory health;The Lancet Respiratory Medicine;2024-09

2. Choice overload for RSV prevention—how to form your opinion;The Lancet Respiratory Medicine;2024-09

3. Respiratory syncytial virus infections in adults: a narrative review;The Lancet Respiratory Medicine;2024-09

4. Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies;The Lancet;2024-09